Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications
- 3 April 2023
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 19 (4) , 203-216
Abstract
Cystic fibrosis (CF) is characterized by mucus accumulation impairing the lungs, gastrointestinal tract, and other organs. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators (ivacaftor, tezacaftor, elexacaftor, and lumacaftor) significantly improve lung function and nutritional status; however, they are substrates, inhibitors, and/or inducers of certain CYP enzymes and transporters, raising the risk of drug-drug interactions (DDI) with common CF medications. A literature search was conducted for DDIs involving CFTR modulators by reviewing new drug applications, drug package inserts, clinical studies, and validated databases of substrates, inhibitors, and inducers. Clinically, CYP3A inducers and inhibitors significantly decrease and increase systemic concentrations of elexacaftor/tezacaftor/ivacaftor, respectively. Additionally, lumacaftor and ivacaftor alter concentrations of CYP3A and P-gp substrates. Potential DDIs without current clinical evidence include ivacaftor and elexacaftor's effect on CYP2C9 and OATP1B1/3 substrates, respectively, and OATP1B1/3 and P-gp inhibitors' effect on tezacaftor. A literature review was conducted using PubMed. Dosing recommendations for CFTR modulators with DDIs are relatively comprehensive; however, recommendations on timing of dosing transition of CFTR modulators when CYP3A inhibitors are initiated or discontinued is incomplete. Certain drug interactions may be managed by choosing an alternative treatment to avoid/minimize DDIs. Next generation CFTR modulator therapies under development are expected to provide increased activity with reduced DDI risk.Keywords
Funding Information
- Cystic Fibrosis Foundation (BERING21AO)
This publication has 56 references indexed in Scilit:
- Effect of Rifampin and Rifabutin on the Pharmacokinetics of Lersivirine and Effect of Lersivirine on the Pharmacokinetics of Rifabutin and 25-O-Desacetyl-Rifabutin in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2012
- Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by ClarithromycinDrug Metabolism and Disposition, 2010
- A Proposal for a Pharmacokinetic Interaction Significance Classification System (PISCS) Based on Predicted Drug Exposure Changes and Its Potential Application to Alert Classifications in Product LabellingClinical Pharmacokinetics, 2009
- High treatment burden in adults with cystic fibrosis: Challenges to disease self-managementJournal of Cystic Fibrosis, 2009
- Contribution of Itraconazole Metabolites to Inhibition of CYP3A4 In VivoClinical Pharmacology & Therapeutics, 2007
- Significance of the Minor Cytochrome P450 3A IsoformsClinical Pharmacokinetics, 2006
- Pharmacokinetic Interactions with RifampicinClinical Pharmacokinetics, 2003
- Effects of the Antifungal Agents on Oxidative Drug MetabolismClinical Pharmacokinetics, 2000
- Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liverJournal of Antimicrobial Chemotherapy, 1996
- The role of individual human cytochrpmes P450 in drug metabolism and clinical responseTrends in Pharmacological Sciences, 1992